CASP9 and cancer: Previous studies reported that miR-769-5p facilitates cisplatin resistance and progression in cancer cells by targeting CASP9 and promoting the ubiquitination-mediated degradation of p53.53 Our results proved that miR-17-5p exerts a regulatory effect that results in an imbalance between the downregulation of Smad7 and the activation of TGFBR1.